Foreign reference pricing frameworks often differ from the way the US has historically valued medical innovation. A more ...
The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of ...
Congress should require the FDA to make DSCSA traceability data accessible and interpretable not only by regulatory agencies ...
The CMS actuaries are—understandably and reasonably—cautious. But recent developments indicate that changes in technology and policy may alter health care delivery and spending—and consequently our ...
Rather than impose one-size-fits-all solutions, federal and state policy makers should craft Medicaid payment policies that ...
Nasal naloxone remains expensive relative to the cost of the underlying drug and continues to strain budgets of public health ...
If an HHS Secretary can seek to unilaterally overturn an evidence-based standard of transgender health care, the same can ...
Similar to opioids and intoxicating hemp-derived THC products, a well-funded and growing kratom industry with lobbying power ...
The finding that Medicaid work requirements could reduce poverty by 1.6 to 2.9 million people, rather than representing their ...
This article concludes a series of five articles on the final 2027 payment rule. It also covers a new lawsuit seeking to void ...
The new rule implementing HR 1’s Medicaid community engagement provision diverges from state expectations. No last-minute ...
Given the high stakes involved, the generic exclusivity period’s effects on competition should be scrutinized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results